Enzolytics Inc (OTCMKTS: ENZC) exited the market with a jump of 27% on Friday. The company recently announced its partnership with Intel for publishing a white paper titled “Optimizing Empathetic A.I. to Cure Deadly Diseases.” The white paper focuses on using artificial intelligence analytic tools from Intel to provide ground-breaking contributions and innovative approach to the field of treatments that target viruses.
The collaborative effort is seen as an approach to penetrate the future of healthcare with processes that evolve from digital technology. The published whitepaper concludes by saying that the use of AI by Enzolytics Inc highlights the need for new approaches in assessing and investigating conserved segments that are essential for the survival of viruses.
It is expected that the use of newer technologies will assist in creating durable and universal effective treatments which target different variants of the viruses.
Meanwhile, ENZC is also soaring in the context of identifying conserved, expectedly immutable sites on a virus named HTLV-1. The company will produce targeted anti-HTLV-1 monoclonal antibodies (mAbs) against the virus.